Finance

Lists
TVRD:NASDAQ
Tvardi Therapeutics Inc
US$ १.०७
०.००%
(०.००) 1D
अक्टोबर १५, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TVRD...
Mkt. cap
१.४३ करोड
Avg. vol.
२.०२ लाख
Volume
५९१.००
52-wk high
US$ ६.६५
52-wk low
US$ ०.९३
EPS
-US$ २.७८
Beta
०.३७
Shares outstanding
१.३३ करोड
No. of employees
१२
Mkt. cap
१.४३ करोड
Avg. vol.
२.०२ लाख
Volume
५९१.००
52-wk high
US$ ६.६५
52-wk low
US$ ०.९३
EPS
-US$ २.७८
Beta
०.३७
Shares outstanding
१.३३ करोड
No. of employees
१२
News stories
From web sources and news partners
About Tvardi Therapeutics Inc
CEO-
Employees१२
Founded२०१७
Headquartersसुगर ल्याण्ड, टेक्सस, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to TVRD in the past 3 months
Buy
Buy
4
Hold
1
Sell
1
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for TVRD in the last 3 months.
Highest
Current US$ १.०७
US$ १४.०० (+१,२०८.४१%)
Average
US$ ८.२० (+६६६.३६%)
Lowest
US$ ३.०० (+१८०.३७%)
Analyst
Recommendation
Action
Price target
Projected
Date
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
US$ १०.००
+८३४.६%
09/15/2026
Elemer Piros
Lucid Capital
Buy
Initiated
US$ १४.००
+१,२०८.४%
09/08/2026
Sara Nik
H.C. Wainwright
Buy
Maintained
US$ ९.००
+७४१.१%
08/21/2026
Unknown Analyst
Cantor Fitzgerald
Hold
Maintained
-
-
08/19/2026
Julian Harrison
BTIG
Buy
Maintained
US$ ५.००
+३६७.३%
08/19/2026
Etzer Darout
Barclays
Sell
Maintained
US$ ३.००
+१८०.४%
08/20/2026
Yasmeen Rahimi
Piper Sandler
Buy
Upgraded
US$ १३.००
+१,११५%
07/08/2026
Ryan Deschner
Raymond James
Buy
Upgraded
US$ १०.००
+८३४.६%
07/08/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
US$ १०.००
+८३४.६%
05/11/2026
Jay Olson
Oppenheimer
Buy
Maintained
US$ १०.००
+८३४.६%
05/11/2026
Steven Seedhouse
Cantor Fitzgerald
Hold
Maintained
-
-
04/01/2026
Christopher Liu
Lucid Capital
Buy
Upgraded
US$ ६.००
+४६०.७%
02/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
३६.०३ लाख
५४.९१ लाख
४९.११ लाख
४०.०२ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२३.३५ लाख
२०.९६ लाख
२१.४० लाख
२६.२७ लाख
Operating expense
५९.३८ लाख
७५.८७ लाख
७०.५१ लाख
६६.२९ लाख
Total operating expenses
५९.३८ लाख
७५.८७ लाख
७०.५१ लाख
६६.२९ लाख
Operating income
-५९.३८ लाख
-७५.८७ लाख
-७०.५१ लाख
-६६.२९ लाख
Other non operating income
-
-
-
-
EBT including unusual items
-५५.२७ लाख
-७२.७५ लाख
-६८.०४ लाख
-६४.५७ लाख
EBT excluding unusual items
-५५.२७ लाख
-७२.७५ लाख
-६८.०४ लाख
-६४.५७ लाख
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-५५.२७ लाख
-७२.७५ लाख
-६८.०४ लाख
-६४.५७ लाख
Net profit margin
-
-
-
-
Earnings per share
-०.५९
-०.७८
-०.७३
-०.६९
Interest and investment income
४.११ लाख
३.१२ लाख
२.४७ लाख
१.७२ लाख
Interest expense
-
-
-
-
Net interest expenses
४.११ लाख
३.१२ लाख
२.४७ लाख
१.७२ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-५९.१४ लाख
-७५.६३ लाख
-७०.२७ लाख
-६६.०६ लाख
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू